Polymer transfected primary myoblasts mediated efficient gene expression and angiogenic proliferation

Journal of Controlled Release

Volumn 142, Issue 1, 2010, Pages 61-69

  Ou, Mei ^a   Kim, Tae il ^a   Yockman, James W ^a   Borden, Bradley A ^a   Bull, David A ^b   Kim, Sung Wan ^a  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Ischemic heart disease; Poly(disulfide amine)s; Skeletal primary myoblasts; VEGF165

Indexed keywords

ANGIOGENIC FACTOR; CELLULAR UPTAKE; CLINICAL APPLICATION; COCULTURE; CYTOTOXIC; GENE DELIVERY; GREEN FLUORESCENCE PROTEINS; IN-VITRO; INFLAMMATORY REACTION; ISCHEMIC HEART DISEASE; LUCIFERASE ASSAYS; LUCIFERASE EXPRESSION; MYOBLAST TRANSPLANTATION; MYOBLASTS; MYOGENESIS; POLYMER CARRIER; POLYMERIC GENE CARRIERS; RAT SKELETAL MUSCLE; THERAPEUTIC ANGIOGENESIS; THERAPEUTIC APPLICATION; TUMORIGENIC MUTATIONS; VIRAL VECTORS;

AMINO ACIDS; BIOACTIVITY; BIODEGRADABLE POLYMERS; CARDIOLOGY; CONFOCAL MICROSCOPY; FLOW CYTOMETRY; FUNCTIONAL POLYMERS; GENE TRANSFER; NUCLEIC ACIDS; ORGANIC COMPOUNDS;

GENE EXPRESSION;

ANGIOGENIC FACTOR; GREEN FLUORESCENT PROTEIN; LUCIFERASE; POLY(CYSTAMINEBISACRYAMIDE HEXANEDIAMINE ARGININE); POLY(CYSTAMINEBISACRYAMIDE HEXANEDIAMINE); POLYETHYLENEIMINE; POLYMER; UNCLASSIFIED DRUG; VASCULOTROPIN 165; VIRUS VECTOR;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; BIODEGRADABILITY; CELL ISOLATION; CELL PROLIFERATION; CELL TRANSPLANTATION; COCULTURE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; ENZYME ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC TRANSFECTION; HEART INFARCTION; IN VITRO STUDY; ISCHEMIC HEART DISEASE; MUSCLE DEVELOPMENT; MYOBLAST; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SKELETAL MUSCLE;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; DISULFIDES; DNA; ENDOTHELIAL CELLS; GENE EXPRESSION; GENE THERAPY; GENES, REPORTER; HUMANS; MUSCLE, SKELETAL; MYOBLASTS; POLYAMINES; RATS; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 76749104649     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.09.021     Document Type: Article

References (44)

1. Haider H.K., Elmadbouh I., Jean-Baptiste M., Ashraf M. Nonviral vector gene modification of stem cells for myocardial repair. Mol. Med. 2008, 14(1-2):79-86.
2. Menasche P. Skeletal myoblast transplantation for cardiac repair. Expert Rev. Cardiovasc. Ther. 2004, 2(1):21-28.
3. Taylor D.A. Cellular cardiomyoplasty with autologous skeletal myoblasts for ischemic heart disease and heart failure. Curr. Control Trials Cardiovasc. Med. 2001, 2(5):208-210.
4. Ott H.C., McCue J., Taylor D.A. Cell-based cardiovascular repair-the hurdles and the opportunities. Basic Res. Cardiol. 2005, 100(6):504-517.
5. Menasche P. Skeletal muscle satellite cell transplantation. Cardiovasc. Res. 2003, 58(2):351-357.
6. Menasche P. Skeletal myoblasts and cardiac repair. J. Mol. Cell. Cardiol. 2008, 45(4):545-553.
7. Blau H.M., Brazelton T.R., Weimann J.M. The evolving concept of a stem cell: entity or function?. Cell 2001, 105(7):829-841.
8. von Degenfeld G., Banfi A., Springer M.L., Blau H.M. Myoblast-mediated gene transfer for therapeutic angiogenesis and arteriogenesis. Br. J. Pharmacol. 2003, 140(4):620-626.
9. Menasche P. Skeletal myoblasts as a therapeutic agent. Prog. Cardiovasc. Dis. 2007, 50(1):7-17.
10. McCue J.D., Swingen C., Feldberg T., Caron G., Kolb A., Denucci C., Prabhu S., Motilall R., Breviu B., Taylor D.A. The real estate of myoblast cardiac transplantation: negative remodeling is associated with location. J. Heart Lung Transplant 2008, 27(1):116-123.
11. Hagege A.A., Marolleau J.P., Vilquin J.T., Alheritiere A., Peyrard S., Duboc D., Abergel E., Messas E., Mousseaux E., Schwartz K., Desnos M., Menasche P. Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the first phase I cohort of patients. Circulation 2006, 114(1 Suppl):I108-I113.
12. Menasche P., Hagege A.A., Scorsin M., Pouzet B., Desnos M., Duboc D., Schwartz K., Vilquin J.T., Marolleau J.P. Myoblast transplantation for heart failure. Lancet 2001, 357(9252):279-280.
13. Hagege A.A., Carrion C., Menasche P., Vilquin J.T., Duboc D., Marolleau J.P., Desnos M., Bruneval P. Viability and differentiation of autologous skeletal myoblast grafts in ischaemic cardiomyopathy. Lancet 2003, 361(9356):491-492.
14. Lei Y., Haider H., Shujia J., Sim E.S. Therapeutic angiogenesis. Devising new strategies based on past experiences. Basic Res. Cardiol. 2004, 99(2):121-132.
15. Henry T.D. Therapeutic angiogenesis. Bmj 1999, 318(7197):1536-1539.
16. Ferrara N., Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18(1):4-25.
17. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9(6):669-676.
18. Haider H., Ye L., Jiang S., Ge R., Law P.K., Chua T., Wong P., Sim E.K. Angiomyogenesis for cardiac repair using human myoblasts as carriers of human vascular endothelial growth factor. J. Mol. Med. 2004, 82(8):539-549.
19. 165 into human skeletal myoblasts: in vitro studies. Exp. Mol. Med. 2003, 35(5):412-420.
20. Rissanen T.T., Yla-Herttuala S. Current status of cardiovascular gene therapy. Mol. Ther. 2007, 15(7):1233-1247.
21. Marshall E. Gene therapy death prompts review of adenovirus vector. Science 1999, 286(5448):2244-2245.
22. Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999, 401(6753):517-518.
23. von Degenfeld G., Banfi A., Springer M.L., Wagner R.A., Jacobi J., Ozawa C.R., Merchant M.J., Cooke J.P., Blau H.M. Microenvironmental VEGF distribution is critical for stable and functional vessel growth in ischemia. FASEB J. 2006, 20(14):2657-2659.
24. Ozawa C.R., Banfi A., Glazer N.L., Thurston G., Springer M.L., Kraft P.E., McDonald D.M., Blau H.M. Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. J. Clin. Invest. 2004, 113(4):516-527.
25. Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis?. Nat. Med. 2000, 6(10):1102-1103.
26. Lee R.J., Springer M.L., Blanco-Bose W.E., Shaw R., Ursell P.C., Blau H.M. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000, 102(8):898-901.
27. Hoffman A.S. The origins and evolution of "controlled" drug delivery systems. J. Control. Release 2008, 132(3):153-163.
28. Mintzer M.A., Simanek E.E. Nonviral vectors for gene delivery. Chem. Rev. 2009, 109(2):259-302.
29. Lin C., Engbersen J.F. Effect of chemical functionalities in poly(amido amine)s for non-viral gene transfection. J. Control. Release 2008, 132(3):267-272.
30. Lynn D.M., Anderson D.G., Putnam D., Langer R. Accelerated discovery of synthetic transfection vectors: parallel synthesis and screening of a degradable polymer library. J. Am. Chem. Soc. 2001, 123(33):8155-8156.
31. Anderson D.G., Lynn D.M., Langer R. Semi-automated synthesis and screening of a large library of degradable cationic polymers for gene delivery. Angew. Chem. Int. Ed. Engl. 2003, 42(27):3153-3158.
32. Lim Y.B., Kim S.M., Suh H., Park J.S. Biodegradable, endosome disruptive, and cationic network-type polymer as a highly efficient and nontoxic gene delivery carrier. Bioconjug. Chem. 2002, 13(5):952-957.
33. Liu Y., Wu D., Ma Y., Tang G., Wang S., He C., Chung T., Goh S. Novel poly(amino ester)s obtained from Michael addition polymerizations of trifunctional amine monomers with diacrylates: safe and efficient DNA carriers. Chem. Commun. (Camb.) 2003, (20):2630-2631.
34. Ou M., Wang X.L., Xu R., Chang C.W., Bull D.A., Kim S.W. Novel biodegradable poly(disulfide amine)s for gene delivery with high efficiency and low cytotoxicity. Bioconjug. Chem. 2008, 19(3):626-633.
35. Kim T.I., Ou M., Lee M., Kim S.W. Arginine-grafted bioreducible poly(disulfide amine) for gene delivery systems. Biomaterials 2009, 30(4):658-664.
36. Banfi A., Springer M.L., Blau H.M. Myoblast-mediated gene transfer for therapeutic angiogenesis. Methods Enzymol. 2002, 346:145-157.
37. Menasche P. Skeletal myoblasts for cardiac repair: act II?*. J. Am. Coll. Cardiol. 2008, 52(23):1881-1883.
38. Murry C.E., Wiseman R.W., Schwartz S.M., Hauschka S.D. Skeletal myoblast transplantation for repair of myocardial necrosis. J. Clin. Invest. 1996, 98(11):2512-2523.
39. Taylor D.A., Atkins B.Z., Hungspreugs P., Jones T.R., Reedy M.C., Hutcheson K.A., Glower D.D., Kraus W.E. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat. Med. 1998, 4(8):929-933.
40. Arsic N., Zacchigna S., Zentilin L., Ramirez-Correa G., Pattarini L., Salvi A., Sinagra G., Giacca M. Vascular endothelial growth factor stimulates skeletal muscle regeneration in vivo. Mol. Ther. 2004, 10(5):844-854.
41. Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B., Behr J.P. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U. S. A. 1995, 92(16):7297-7301.
42. Wang D.A., Narang A.S., Kotb M., Gaber A.O., Miller D.D., Kim S.W., Mahato R.I. Novel branched poly(ethylenimine)-cholesterol water-soluble lipopolymers for gene delivery. Biomacromolecules 2002, 3(6):1197-1207.
43. Zhong Z., Feijen J., Lok M.C., Hennink W.E., Christensen L.V., Yockman J.W., Kim Y.H., Kim S.W. Low molecular weight linear polyethylenimine-b-poly(ethylene glycol)-b-polyethylenimine triblock copolymers: synthesis, characterization, and in vitro gene transfer properties. Biomacromolecules 2005, 6(6):3440-3448.
44. Suzuki K., Murtuza B., Smolenski R.T., Sammut I.A., Suzuki N., Kaneda Y., Yacoub M.H. Cell transplantation for the treatment of acute myocardial infarction using vascular endothelial growth factor-expressing skeletal myoblasts. Circulation 2001, 104(12 Suppl 1):I207-I212.